BACKGROUND: The degree of cross-immunity between human papillomavirus (HPV) types is fundamental both to the epidemiological dynamics of HPV and to the impact of HPV vaccination. Epidemiological data on HPV infections has been repeatedly interpreted as inconsistent with cross-immunity. METHODS: We reevaluate the epidemiological data using a model to determine the odds ratios of multiple to single infections expected in the presence or absence of cross-immunity. We simulate a virtual longitudinal survey to determine the effect cross-immunity has on the prevalence of multiple infections. We calibrate our model to epidemiological data and estimate the extent of type replacement following vaccination against specific HPV types. RESULTS: We find that cross-immunity can produce odds ratios of infection comparable with epidemiological observations. We show that the sample sizes underlying existing surveys have been insufficient to identify even intense cross-immunity. We also find that the removal of HPV type 16, type 18, and types 6 and 11 would increase the prevalence of nontargeted types by 50%, 29%, and 183%, respectively. CONCLUSIONS: Cross-immunity between HPV types is consistent with epidemiological data, contrary to previous interpretations. Cross-immunity may cause significant type replacement following vaccination, and therefore should be considered in future vaccine studies and epidemiological models.
BACKGROUND: The degree of cross-immunity between human papillomavirus (HPV) types is fundamental both to the epidemiological dynamics of HPV and to the impact of HPV vaccination. Epidemiological data on HPV infections has been repeatedly interpreted as inconsistent with cross-immunity. METHODS: We reevaluate the epidemiological data using a model to determine the odds ratios of multiple to single infections expected in the presence or absence of cross-immunity. We simulate a virtual longitudinal survey to determine the effect cross-immunity has on the prevalence of multiple infections. We calibrate our model to epidemiological data and estimate the extent of type replacement following vaccination against specific HPV types. RESULTS: We find that cross-immunity can produce odds ratios of infection comparable with epidemiological observations. We show that the sample sizes underlying existing surveys have been insufficient to identify even intense cross-immunity. We also find that the removal of HPV type 16, type 18, and types 6 and 11 would increase the prevalence of nontargeted types by 50%, 29%, and 183%, respectively. CONCLUSIONS: Cross-immunity between HPV types is consistent with epidemiological data, contrary to previous interpretations. Cross-immunity may cause significant type replacement following vaccination, and therefore should be considered in future vaccine studies and epidemiological models.
Authors: Susanne Krüger Kjaer; Christian Munk; Jeanette Falck Winther; Hans Ole Jørgensen; Chris J L M Meijer; Adriaan J C van den Brule Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer Journal: Int J Cancer Date: 2004-08-20 Impact factor: 7.396
Authors: Harriet Richardson; Gail Kelsall; Pierre Tellier; Hélène Voyer; Michal Abrahamowicz; Alex Ferenczy; François Coutlée; Eduardo L Franco Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-06 Impact factor: 4.254
Authors: Guilherme S Ribeiro; Joice N Reis; Soraia M Cordeiro; Josilene B T Lima; Edilane L Gouveia; Maya Petersen; Kátia Salgado; Hagamenon R Silva; Rosemeire Cobo Zanella; Samanta C Grassi Almeida; Maria Cristina Brandileone; Mitermayer G Reis; Albert I Ko Journal: J Infect Dis Date: 2002-12-13 Impact factor: 5.226
Authors: Sylvia L Ranjeva; Edward B Baskerville; Vanja Dukic; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano; Greg Dwyer; Sarah Cobey Journal: Proc Natl Acad Sci U S A Date: 2017-12-05 Impact factor: 11.205
Authors: Irene Man; Kari Auranen; Jacco Wallinga; Johannes A Bogaards Journal: Philos Trans R Soc Lond B Biol Sci Date: 2019-05-27 Impact factor: 6.237
Authors: David P Durham; Martial L Ndeffo-Mbah; Laura A Skrip; Forrest K Jones; Chris T Bauch; Alison P Galvani Journal: Proc Natl Acad Sci U S A Date: 2016-04-18 Impact factor: 11.205
Authors: Erik Bernard; Margarita Pons-Salort; Michel Favre; Isabelle Heard; Elisabeth Delarocque-Astagneau; Didier Guillemot; Anne C M Thiébaut Journal: BMC Infect Dis Date: 2013-08-13 Impact factor: 3.090
Authors: Henrike J Vriend; Johannes A Bogaards; Fiona R M van der Klis; Mirte Scherpenisse; Hein J Boot; Audrey J King; Marianne A B van der Sande Journal: PLoS One Date: 2013-04-23 Impact factor: 3.240